Zoetis Inc.
Analysis
Four calls tell one story: the franchises that built Zoetis met price-driven competition in a pet-care market that stopped growing, and every report cut the outlook. Livestock, diagnostics and cost cuts carry the company until the pipeline lands in 2027. How much of Zoetis' guidance cut came from U.S. dermatology?
- The two franchises that built Zoetis are now shrinking.
Dermatology fell 16% in Q2 FY2026 and Simparica was flat, after years of growth. Rivals now compete on price in a market that is not expanding — management said in Q1 the new entrants "have not yet translated into overall market expansion." How much U.S. derm share has Zoetis lost since the new JAK launched?
- The year's outlook has been cut at every report.
It expected growth in February and guided to a shrinking year by August, after July sales showed no stabilization. The products meant to reverse that arrive at the end of 2027, so the next quarters run on defence, cost cuts and buybacks.
- Livestock and diagnostics are holding the company up.
Livestock grew 11% and diagnostics 12% in Q2 FY2026 while pet care fell. But the U.S. livestock quarter leaned on screwworm demand management calls transitory, so the cushion under pet care is thinner than it looks. How much of the U.S. livestock surge was screwworm demand that won't repeat?
- Livestock and diagnostics growthThe bull case is that cattle, poultry, fish and diagnostics are growing fast enough to keep total revenue near flat while companion animal works through its downturn.
- Long-acting OA pain launchesNew long-acting osteoarthritis products and a wider dermatology lineup give Zoetis fresh products to defend clinics where its older brands are losing ground.
- Cost cuts and buybacksCost cuts and a smaller share count from buybacks can keep earnings per share from falling as much as revenue, cushioning the downturn.
- Price-based competitionThe bear case is that new entrants are winning on price in a market that is no longer expanding, so Zoetis must discount to hold volume and loses revenue either way.
- Falling clinic visitsPet owners are cutting routine clinic visits after several years of price increases, which shrinks the pool of new patients the companion animal franchises need.
- Repeated guidance cutsManagement has cut its outlook twice in a year and still assumes the pressure persists, with no evidence yet that the companion animal decline has found a floor.
| Politician | Transaction | Amount | Traded | Filed |
|---|---|---|---|---|
Donald Trump Republican · Executive | Purchase | ≥$15K | Aug 28 | Oct 8 |
Donald Trump Republican · Executive | Sale | ≥$500K | Aug 21 | Oct 8 |
Donald Trump Republican · Executive | Purchase | ≥$1K | Aug 17 | Oct 8 |
Donald Trump Republican · Executive | Sale | ≥$1K | Aug 10 | Oct 8 |
Donald Trump Republican · Executive | Purchase | ≥$500K | Aug 10 | Oct 8 |
Congressional trading data provided by QuiverQuant
How Zoetis turned $9.5B of revenue into $3.6B of operating income.
| Revenue | ||
|---|---|---|
| Horses | $6.3B | ▲ 4.84% YoY |
| Cattle | $1.5B | ▼ 2.55% YoY |
| Swine | $466.0M | ▼ 9.69% YoY |
| Poultry | $432.0M | ▼ 18.03% YoY |
| Dogs and Cats | $304.0M | ▲ 6.67% YoY |
| Fish | $286.0M | ▲ 18.18% YoY |
| Total revenue | $9.5B | |
| Gross profit | $6.8B | 71.8% |
| Operating income | $3.6B | 38.0% |